2022
Kotla NG, Singh R, Baby BV, Rasala S, Rasool J, Hynes SO, Martin D, Egan LJ, Vemula PK, Jala VR, Rochev Y, Pandit A.
2022. Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease.. Biomaterials. 281:121364. DOI:10.1016/j.biomaterials.2022.121364.
Ghosh S, Singh R, Vanwinkle ZMatthew, Guo H, Vemula PKumar, Goel A, Haribabu B, Jala VRao.
2022. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.. Theranostics. 12(12):5574-5595. DOI:10.7150/thno.70754.
2020
2019
Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, Hiwale AA, Saiyed T, Patel P, Vijay-Kumar M, Langille MGI, Douglas GM, Cheng X, Rouchka EC, Waigel SJ, Dryden GW, Alatassi H, Zhang H-G, Haribabu B, Vemula PK et al..
2019. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway.. Nat Commun. 10(1):89. DOI:10.1038/s41467-018-07859-7.
2017
Singh R, Hegde B, Von Baby B, Sadeep C, Kotla N, Chandrasekar B, Marepally S, Bodduluri H, Vemula PK, Jala VR.
2017. Targeted delivery of microbial metabolite, urolithin A protects from chemically (DSS or TNBS) induced colitis in pre-clinical models. The Journal of Immunology. 198:65.6–65.6.
2016